Enhancement of immune responses by 4-1bb-binding agents
View Patent ↗This invention features methods of enhancing immune responses in mammalian subjects and in vitro methods of enhancing the response of a T cell. Also embodied by the invention are methods of receiving and preventing the induction of energy in T cells.
1. A method of generating an enhanced immune response in a subject, the method comprising administering to the subject:
(a) an immunogenic stimulus, wherein the immunogenic stimulus comprises a polypeptide and does not comprise a tumor cell; and
(b) an agonistic antibody that binds to 4-1BB.
2. The method of claim 1 , wherein the immunogenic stimulus is (a) a tumor-associated antigen (TAA) or (b) a functional fragment of a TAA.
3. The method of claim 2 , wherein the TAA is a molecule produced by a cancer cell selected from the group consisting of a leukemia, a lymphoma, a neurological cancer, a melanoma, a breast cancer, a lung cancer, a head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a prostate cancer, a renal cell cancer, a bone cancer, and a vascular cancer cell.
4. The method of claim 1 , wherein the immunogenic stimulus is a molecule produced by an infectious microorganism.
5. The method of claim 4 , wherein the infectious microorganism is a virus.
6. The method of claim 5 , wherein the virus is a retrovirus.
7. The method of claim 4 , wherein the infectious microorganism is selected from the group consisting of a bacterium, a fungus, and a protozoan parasite.
8. The method of claim 1 , wherein the subject is a human.
9. The method of claim 1 , wherein the immune response is a response of a T cell.
10. The method of claim 9 , wherein the T cell is a CD8+ T cell.
11. The method of claim 9 , wherein the T cell is CD4+ T cell.
12. The method of claim 1 , wherein the immunogenic stimulus is a TAA, a peptide-epitope of a TAA, or a heat shock protein bound to peptide-epitope of a protein expressed by a tumor cell.
13. An in vitro method of activating a T cell, the method comprising:
(a) providing a cell sample comprising a T cell; and
(b) culturing the cell sample with an immunogenic stimulus and an agonistic 4-1BB-binding agent.
14. A method of preventing induction of energy or of reversing anergy in a T cell, the method comprising contacting the T cell with:
(a) an immunogenic stimulus, wherein the immunogenic stimulus comprises a polypeptide and does not comprise a tumor cell; and
(b) an agonistic antibody that binds to 4-1BB.
15. The method of claim 14 , wherein the contacting is in vitro.
16. The method of claim 14 , wherein the T cell is in a mammal.
17. The method of claim 16 , wherein the mammal is a human.
18. The method of claim 16 , wherein the contacting comprises administering to the mammal:
(a) the immunogenic stimulus and the agonistic antibody; or
(b) the immunogenic stimulus and a nucleic acid encoding the agonistic 4-1BB antibody.
19. The method of claim 18 , wherein the method comprises administering a cell transfected or transduced with a nucleic acid encoding the antibody to the mammal, wherein the cell is a cell, or a progeny of a cell, that prior to the transfection or the transduction, was obtained from the mammal.
20. The method of claim 14 , wherein the immunogenic stimulus is (a) a tumor-associated antigen (TAA) or (b) a functional fragment of a TAA.
21. The method of claim 20 , wherein the TAA is a molecule produced by a cancer cell selected from the group consisting of a leukemia, a lymphoma, a neurological cancer, a melanoma, a breast cancer, a lung cancer, a head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a prostate cancer, a renal cell cancer, a bone cancer, and a vascular cancer cell.
22. The method of claim 14 , wherein the immunogenic stimulus is a molecule produced by an infectious microorganism.
23. The method of claim 22 , wherein the infectious microorganism is a virus.
24. The method of claim 23 , wherein the virus is a retrovirus.
25. The method of claim 22 , wherein the infectious microorganism is selected from the group consisting of a bacterium, a fungus, and a protozoan parasite.
26. The method of claim 14 , wherein the T cell is a CD8+ T cell.
27. The method of claim 14 , wherein the T cell is CD4+ T cell.
28. The method of claim 14 , wherein the immunogenic stimulus is a TAA, a peptide-epitope of a TAA, or a heat shock protein bound to peptide-epitope of a protein expressed by a tumor cell.